MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.hpb.2019.12.008

Медицинская библиотека · HPB : the official journal of the International Hepato Pancreato Biliary Association · 2019

Hepatopancreatoduodenectomy -a controversial treatment for bile duct and gallbladder cancer from a European perspective.

D'Souza Melroy A, Valdimarsson Valentinus T, Campagnaro Tommaso, Cauchy Francois, Chatzizacharias Nikolaos A, D'Hondt Mathieu, Dasari Bobby, Ferrero Alessandro, Franken Lotte C, Fusai Giuseppe, Guglielmi Alfredo, Hagendoorn Jeroen, Hidalgo Salinas Camila, Hoogwater Frederik J H, Jorba Rosa, Karanjia Nariman, Knoefel Wolfram T, Kron Philipp, Lahiri Rajiv, Langella Serena, Le Roy Bertrand, Lehwald-Tywuschik Nadja, Lesurtel Mickael, Li Jun, Lodge J Peter A, Martinou Erini, Molenaar Izaak Q, Nikov Andrej, Poves Ignasi, Rassam Fadi, Russolillo Nadia, Soubrane Olivier, Stättner Stefan, van Dam Ronald M, van Gulik Thomas M, Serrablo Alejandro, Gallagher Tom M, Sturesson Christian, E-AHPBA scientific and research committee

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Hepatopancreatoduodenectomy (HPD) is an aggressive operation for treatment of advanced bile duct and gallbladder cancer associated with high perioperative morbidity and mortality, and uncertain oncological benefit in terms of survival. Few reports on HPD from Western centers exist. The purpose of this study was to evaluate safety and efficacy for HPD in European centers.

METHOD: Members of the European-African HepatoPancreatoBiliary Association were invited to report all consecutive patients operated with HPD for bile duct or gallbladder cancer between January 2003 and January 2018. The patient and tumor characteristics, perioperative and survival outcomes were analyzed.

RESULTS

In total, 66 patients from 19 European centers were included in the analysis. 90-day mortality rate was 17% and 13% for bile duct and gallbladder cancer respectively. All factors predictive of perioperative mortality were patient and disease-specific. The three-year overall survival excluding 90-day mortality was 80% for bile duct and 30% for gallbladder cancer (P = 0.013). In multivariable analysis R0-resection had a significant impact on overall survival.

CONCLUSION

HPD, although being associated with substantial perioperative mortality, can offer a survival benefit in patient subgroups with bile duct cancer and gallbladder cancer. To achieve negative resection margins is paramount for an improved survival outcome.

Для цитирования: D'Souza Melroy A, Valdimarsson Valentinus T, Campagnaro Tommaso, Cauchy Francois, Chatzizacharias Nikolaos A, D'Hondt Mathieu, Dasari Bobby, Ferrero Alessandro, Franken Lotte C, Fusai Giuseppe, Guglielmi Alfredo, Hagendoorn Jeroen, Hidalgo Salinas Camila, Hoogwater Frederik J H, Jorba Rosa, Karanjia Nariman, Knoefel Wolfram T, Kron Philipp, Lahiri Rajiv, Langella Serena, Le Roy Bertrand, Lehwald-Tywuschik Nadja, Lesurtel Mickael, Li Jun, Lodge J Peter A, Martinou Erini, Molenaar Izaak Q, Nikov Andrej, Poves Ignasi, Rassam Fadi, Russolillo Nadia, Soubrane Olivier, Stättner Stefan, van Dam Ronald M, van Gulik Thomas M, Serrablo Alejandro, Gallagher Tom M, Sturesson Christian, E-AHPBA scientific and research committee. Hepatopancreatoduodenectomy -a controversial treatment for bile duct and gallbladder cancer from a European perspective.. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2019. DOI: 10.1016/j.hpb.2019.12.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.